HCM
SAGE

Highbridge Capital Management’s Sage Therapeutics SAGE Stock Holding History

Highbridge Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,390
Closed -$229K – 1646
2017
Q4 		$229K Buy
+1,390
New +$135K ﹤0.01% 1411
2016
Q2 		– Sell
-11,490
Closed -$369K – 1705
2016
Q1 		$369K Buy
+11,490
New +$404K 0.01% 1097
2015
Q4 		– Sell
-11,531
Closed -$488K – 1767
2015
Q3 		$488K Buy
+11,531
New +$711K 0.01% 1038

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Highbridge Capital Management's SAGE Position: Q1 2018 in Review

Highbridge Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2018, closing a stake of 1,390 shares — an estimated $229K sold.

Highbridge Capital Management first reported a position in SAGE in Q3 2015 and held it in 3 quarters. The position peaked at $488K in Q3 2015. 251 funds tracked by Wall St. Rank hold SAGE as of Q1 2018.

  • Highbridge Capital Management reported no remaining Sage Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 1,390 Sage Therapeutics shares in Q1 2018, an estimated $229K.
  • Highbridge Capital Management first reported a position in Sage Therapeutics in Q3 2015 and held it in 3 quarters.
  • Highbridge Capital Management's Sage Therapeutics position peaked at $488K in Q3 2015.
  • 251 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.